Mourabit Halima, Author at MediaMedic

Breaking Ground in STS Treatment: Dr. Yuhong Zhou Champions Anti-Angiogenic TKIs at CSCO 2024

By Mourabit Halima 2024.10.22

Soft tissue sarcoma (STS) is a highly heterogeneous group of tumors with complex pathology, and the benefits of first-line chemotherapy, primarily anthracycline-based, are limited. As a result, patient prognosis remains poor overall. In recent years, anti-angiogenic tyrosine kinase inhibitors (TKIs) have emerged as a promising option for second- and later-line treatments, with potential for expansion into the first-line setting. At the 2024 CSCO conference, Dr. Yuhong Zhou from Zhongshan Hospital, Fudan University, delivered a detailed presentation on the latest research in anti-angiogenic TKIs for STS. In an exclusive interview with Oncology Frontier, she also shared insights into the advancements in diagnosis and treatment in this field.

ISDE 2024 | Revolutionizing Esophageal Cancer Treatment: FLOT Regimen Emerges as a Frontrunner in ISDE 2024

By Mourabit Halima 2024.10.22

In a special interview at the 20th International Society for Diseases of the Esophagus (ISDE) conference, Dr. Jens Hoeppner from Bielefeld University in Germany shared his insights on the FLOT regimen's clinical benefits over the CROSS regimen in the treatment of locally advanced resectable esophageal adenocarcinoma. He also discussed the potential integration of immunotherapy and the 'watch and wait' strategy in future treatments.

Advancements in Targeted Therapies for Mycosis Fungoides and Sézary Syndrome: Dr. Lanfang Li and Professor Zhuang Weiyun Share Key Insights

By Mourabit Halima 2024.10.22

In a recent interview, Dr. Lanfang Li and Professor Zhuang Weiyun from the University of California, San Francisco discussed breakthroughs in treating Mycosis Fungoides (MF) and Sézary Syndrome (SS), focusing on the efficacy of brentuximab vedotin and mogamulizumab. They highlighted the importance of targeting different disease compartments and leveraging new drugs to improve patient outcomes. With advancements in targeted therapies and an emphasis on early diagnosis, the experts emphasized the need for multidisciplinary collaboration to better manage these rare but challenging conditions.

Exploring Evolving Strategies for HR-Positive Breast Cancer with Dr. Virginia Kaklamani

By Mourabit Halima 2024.10.22

In a recent interview, Dr. Virginia Kaklamani discussed the rapidly advancing landscape of hormone receptor-positive breast cancer treatments. With the emergence of novel medications like CDK4-6 inhibitors, oral SERDs, and PI3K/AKT pathway inhibitors, she emphasized the need for NGS testing to guide treatment decisions. Dr. Kaklamani highlighted the unique efficacy and safety profiles of alpelisib, inovolacib, and capivacertib, and provided insights on selecting the most suitable therapy based on specific genetic mutations.

CSCO 2024 | Dr. Yilong Wu: How to Make Targeted Therapy Decisions for NSCLC Patients with EGFR Mutations

By Mourabit Halima 2024.10.21

The 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held from September 25 to 29, 2024, in Xiamen. During the conference, several forums on lung cancer covered cutting-edge research and developments in the field. During the event, Oncology Frontier invited Dr. Yilong Wu from Guangdong Provincial People’s Hospital to share his insights on making targeted therapy decisions for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

CSCO 2024丨Dr. Jun Ma Reflects on CSCO’s Glorious Journey: China’s Rise in Oncology on the Global Stage

By Mourabit Halima 2024.10.21

From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference will showcase major research advancements and developments in the field both domestically and internationally. Over the past 20 years, CSCO has continuously led the development of clinical oncology in China, with many experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series in response to CSCO's call, inviting Chinese scholars to revisit past stories. In this issue, we have invited Dr. Jun Ma, Chairman of the Supervisory Board of CSCO and Director of the Harbin Institute of Hematology and Oncology, to share his touching stories of "growing with CSCO."

CUA 2024 | Dr. Eamonn Rogers: Patient-Centered Care and Exploring Future Strategies for Prostate Cancer

By Mourabit Halima 2024.10.21

Prostate cancer is a common malignant tumor in elderly men. However, with continuous advancements in diagnostic and treatment strategies, patient survival rates have improved, and patient-centered care has become a key focus in oncology. During the recent CUA Annual Meeting, Urology Frontier invited Dr. Eamonn Rogers from the National University of Ireland to share his thoughts on the future of prostate cancer research, the importance of patient-reported outcomes (PROs), and evolving models of care to meet modern medical challenges.

ESMO 2024丨Dr. Fufu Zheng: Progress in Urologic Cancer Research and Explorations Likely to Change Clinical Practice for Advanced Renal Cancer

By Mourabit Halima 2024.10.21

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting is being held from September 13-17 in Barcelona, Spain. Several key studies in the field of urologic cancers have attracted significant attention at the conference. Urology Frontier invited Dr. Fufu Zheng from the Department of Urology at The First Affiliated Hospital , Sun Yat-sen University to provide in-depth analysis of the major research findings presented at the conference. Professor Zheng shared his team’s latest breakthroughs in the field of urology, particularly regarding the frontier advancements in combination therapies for advanced renal cell carcinoma (RCC), while also offering insights into the promising future of RCC treatment.

Revolutionizing NSCLC Treatment: Dr. Baohui Han and Dr. Mitsudomi Unveil New Frontiers in Immunotherapy Strategies

By Mourabit Halima 2024.10.20

The 27th National Clinical Oncology Conference and 2024 CSCO Academic Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. During this event, Dr. Tetsuya Mitsudomi, who has led several large-scale immunotherapy clinical trials, gave an academic report on the latest progress in immunotherapy for NSCLC. Oncology Frontier invited Dr. Baohui Han from Shanghai Chest Hospital to have an in-depth conversation with Dr. Tetsuya Mitsudomi from Kindai University School of Medicine in Japan. They shared insights on decision-making strategies for perioperative treatment, prognostic biomarkers, and managing adverse events in NSCLC immunotherapy.

ESMO 2024 | Dr. Wei Yu: Advances in Perioperative Immunotherapy and Combined Immunotherapy for Muscle-Invasive Urothelial Carcinoma Patients

By Mourabit Halima 2024.10.20

Research has shown that nearly 50% of patients with muscle-invasive urothelial carcinoma (MIUC) will experience recurrence with distant metastases. Therefore, exploring perioperative treatments for muscle-invasive bladder cancer (MIBC) is crucial to improving patient outcomes. The 2024 European Society for Medical Oncology (ESMO) Congress, held from September 13 to 17 in Barcelona, Spain, highlighted several advances in perioperative immunotherapy and combination immunotherapy for MIUC patients. Dr. Wei Yu and Dr. Qi Tang from Peking University First Hospital shared their insights on this important topic.